Should People Without Diabetes Wear a Glucose Monitor? The Evidence Behind the Trend

A small adhesive sensor worn on the back of the upper arm, transmitting real-time blood glucose readings to a smartphone every few minutes — continuous glucose monitors (CGMs) were engineered to help people with Type 1 and Type 2 diabetes manage a condition that can be life-threatening without careful monitoring. Today, they are increasingly appearing on the arms of people who have never been diagnosed with any metabolic disorder.

Driven in part by high-profile endorsements from performance coaches, longevity physicians, and wellness influencers, and made more accessible by companies such as Levels, Nutrisense, and Abbott's Lingo (launched specifically for the non-diabetic consumer market), CGM adoption among metabolically healthy Americans is growing at a pace that has outrun the clinical evidence base. The central question this raises is neither trivial nor easily resolved: does wearing one of these devices offer genuine, actionable health value to someone without diabetes or prediabetes, or does it primarily generate data noise and metabolic anxiety?

How CGMs Actually Work

Continuous glucose monitors measure interstitial fluid glucose — the glucose concentration in the fluid surrounding cells beneath the skin — rather than blood glucose directly. The sensor communicates with a reader or smartphone application, typically updating readings every five to fifteen minutes. Modern devices such as the Dexcom G7 and the Abbott FreeStyle Libre 3 are accurate enough for clinical diabetes management; their accuracy in the lower glucose ranges typical of metabolically healthy individuals is generally adequate but somewhat less validated for that specific population.

The data generated includes not just point-in-time glucose values, but patterns: how quickly glucose rises after eating (the glycemic response), how long it remains elevated, and how it responds to exercise, sleep, stress, and other physiological inputs. For people with diabetes, this granular information is unambiguously valuable. For everyone else, the clinical significance of that data depends heavily on context and interpretation.

What the Research Actually Supports

The honest assessment of the published literature on CGM use in non-diabetic populations is this: the evidence is suggestive in some domains, genuinely promising in a few specific applications, and largely insufficient to support broad population-level recommendations.

Metabolic risk identification. Perhaps the strongest case for CGM use outside of diagnosed diabetes involves the identification of individuals with impaired glucose regulation who would not be caught by conventional fasting glucose or HbA1c testing. Research has demonstrated that postprandial glucose spikes — elevations occurring after meals — can be abnormal in individuals whose fasting glucose and HbA1c values fall within the normal range. A 2018 study published in PLOS Biology found substantial inter-individual variability in glycemic responses to identical foods among healthy adults, suggesting that standardized dietary guidelines may fail to capture personal metabolic variation. CGMs can surface this kind of data in a way that a quarterly blood draw cannot.

Athletic performance and recovery. Among competitive and recreational athletes, there is a reasonable theoretical basis for monitoring glucose during training. Carbohydrate availability is a primary determinant of performance in endurance sports, and understanding individual glucose kinetics during sustained exercise could theoretically inform fueling strategies. However, peer-reviewed trials specifically examining CGM-guided nutrition protocols in non-diabetic athletes are limited in number and modest in sample size. Most of the enthusiasm in this space is extrapolated from mechanistic reasoning rather than robust outcome data.

Energy and cognitive function. A frequently cited benefit among CGM users is an improved understanding of how food choices affect subjective energy levels and mental clarity. This is plausible — postprandial glucose variability has been associated with fatigue and reduced cognitive performance in some studies. Yet it is important to distinguish between an association observed in research populations and a clinically validated, individually actionable signal. Feeling tired after lunch may correlate with a glucose spike, but it may also reflect sleep quality, hydration, meal composition, or any number of other variables that a glucose monitor cannot capture.

Weight management. Some proponents argue that CGM feedback can support weight loss by making individuals more aware of glycemic responses to specific foods, thereby encouraging dietary modification. Preliminary data from companies like Levels has been cited in this context, though much of it comes from proprietary observational analyses rather than independently replicated randomized controlled trials — an important distinction for evidence-conscious consumers.

The Case for Caution

Several legitimate concerns accompany the expansion of CGM use into non-diabetic populations, and they deserve equal weight in any balanced assessment.

Pathologizing normal physiology. Glucose fluctuations — including moderate postprandial spikes — are a normal feature of healthy metabolism. The human body is designed to manage these variations through insulin secretion and other regulatory mechanisms. When individuals without metabolic dysfunction observe their glucose rising after eating a piece of fruit and respond with dietary restriction or anxiety, the device may be generating harm rather than benefit. Several endocrinologists and diabetes educators have raised this concern publicly, noting that CGM reference ranges were calibrated for diabetic populations and may not translate meaningfully to healthy physiology.

Data interpretation without clinical context. A CGM generates continuous data, but data is not inherently equivalent to insight. Without clinical training or guidance from a qualified healthcare provider, users may misinterpret normal variation as pathology, make unnecessary dietary restrictions, or develop an unhealthy preoccupation with metabolic metrics. This phenomenon — sometimes described as "quantified self" anxiety — has been observed in patients presenting to primary care with self-diagnosed metabolic concerns based on consumer device data.

Cost and access equity. Consumer-market CGMs typically cost between $100 and $200 per month without insurance coverage, which is not reimbursable for non-diabetic users under most American health insurance plans. Framing this technology as a general wellness tool without acknowledging its cost barrier risks creating a two-tiered health optimization landscape accessible primarily to higher-income individuals.

Privacy considerations. Continuous health monitoring generates sensitive personal data. Consumers should review the data privacy policies of CGM platform providers carefully, particularly regarding whether glucose and dietary data may be shared with third parties, sold to insurers, or used for targeted advertising. These are not hypothetical concerns — they reflect the broader landscape of digital health data governance in the United States, where comprehensive federal health data privacy protections do not currently extend to consumer wellness applications.

Who Might Legitimately Benefit

Despite the legitimate caveats above, certain individuals without a diabetes diagnosis may derive meaningful, evidence-aligned value from a trial period of CGM use:

• Those with a strong family history of Type 2 diabetes or metabolic syndrome, who may benefit from early identification of postprandial dysregulation before it registers on standard screening tests.
• Individuals with polycystic ovary syndrome (PCOS), a condition associated with insulin resistance in which glucose monitoring may support dietary management.
• Endurance athletes with specific fueling optimization goals, provided they work with a sports dietitian capable of interpreting the data.
• Patients with unexplained fatigue, brain fog, or reactive hypoglycemia symptoms, for whom a two-to-four-week monitoring period may provide clinically useful data to share with their physician.

For the majority of metabolically healthy Americans without these specific indications, the evidence does not currently support CGM use as a routine wellness practice — though it also does not categorically preclude it for those who approach the data thoughtfully and with professional guidance.

The Bottom Line

Continuous glucose monitoring is neither a revolutionary wellness tool for everyone nor an entirely misguided trend. It occupies a genuinely ambiguous space in which the technology has outpaced the clinical evidence, and where both enthusiastic proponents and reflexive skeptics tend to overstate their cases.

The most defensible position, from an evidence-based standpoint, is selective: CGMs offer real potential for specific populations and well-defined applications, but they are not a substitute for comprehensive metabolic evaluation, and their data should be interpreted within a clinical framework rather than through a consumer app interface alone. If you are considering trying one, a conversation with your physician or a registered dietitian is a more valuable first step than a subscription checkout.